A detailed history of Invesco Ltd. transactions in Blueprint Medicines Corp stock. As of the latest transaction made, Invesco Ltd. holds 809,600 shares of BPMC stock, worth $89.3 Million. This represents 0.02% of its overall portfolio holdings.

Number of Shares
809,600
Previous 417,584 93.88%
Holding current value
$89.3 Million
Previous $38.5 Million 99.39%
% of portfolio
0.02%
Previous 0.01%

Shares

21 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 14, 2024

BUY
$73.17 - $99.79 $28.7 Million - $39.1 Million
392,016 Added 93.88%
809,600 $76.8 Million
Q4 2023

Feb 12, 2024

BUY
$43.96 - $92.84 $15.2 Million - $32.1 Million
345,554 Added 479.74%
417,584 $38.5 Million
Q3 2023

Nov 13, 2023

BUY
$46.9 - $66.0 $211,096 - $297,066
4,501 Added 6.67%
72,030 $3.62 Million
Q2 2023

Aug 11, 2023

SELL
$42.2 - $66.37 $220,579 - $346,915
-5,227 Reduced 7.18%
67,529 $4.27 Million
Q1 2023

May 12, 2023

BUY
$37.97 - $50.0 $124,959 - $164,550
3,291 Added 4.74%
72,756 $3.27 Million
Q4 2022

Feb 13, 2023

BUY
$41.06 - $66.48 $136,565 - $221,112
3,326 Added 5.03%
69,465 $3.04 Million
Q3 2022

Nov 14, 2022

SELL
$49.93 - $77.7 $5.26 Million - $8.19 Million
-105,366 Reduced 61.44%
66,139 $4.36 Million
Q2 2022

Aug 15, 2022

BUY
$45.23 - $70.15 $4.33 Million - $6.71 Million
95,647 Added 126.09%
171,505 $8.66 Million
Q1 2022

May 16, 2022

SELL
$54.1 - $110.08 $1.15 Million - $2.34 Million
-21,243 Reduced 21.88%
75,858 $4.85 Million
Q4 2021

Feb 14, 2022

SELL
$94.25 - $115.99 $4.25 Million - $5.23 Million
-45,126 Reduced 31.73%
97,101 $10.4 Million
Q3 2021

Nov 15, 2021

SELL
$80.98 - $109.47 $1.47 Million - $1.98 Million
-18,105 Reduced 11.29%
142,227 $14.6 Million
Q2 2021

Aug 17, 2021

SELL
$82.78 - $101.0 $99.5 Million - $121 Million
-1,202,402 Reduced 88.23%
160,332 $14.1 Million
Q1 2021

May 17, 2021

BUY
$90.71 - $108.28 $1.13 Million - $1.35 Million
12,463 Added 0.92%
1,362,734 $132 Million
Q4 2020

Feb 16, 2021

BUY
$92.08 - $124.48 $9.19 Million - $12.4 Million
99,755 Added 7.98%
1,350,271 $151 Million
Q3 2020

Nov 16, 2020

SELL
$66.45 - $92.7 $191,442 - $267,068
-2,881 Reduced 0.23%
1,250,516 $116 Million
Q2 2020

Aug 14, 2020

SELL
$57.09 - $79.27 $33,968 - $47,165
-595 Reduced 0.05%
1,253,397 $97.8 Million
Q1 2020

May 15, 2020

SELL
$48.11 - $82.22 $13.7 Million - $23.3 Million
-283,839 Reduced 18.46%
1,253,992 $73.3 Million
Q4 2019

Feb 14, 2020

BUY
$66.73 - $82.59 $1.21 Million - $1.49 Million
18,096 Added 1.19%
1,537,831 $123 Million
Q3 2019

Nov 14, 2019

SELL
$72.9 - $101.41 $20.5 Million - $28.5 Million
-281,367 Reduced 15.62%
1,519,735 $112 Million
Q2 2019

Aug 14, 2019

BUY
$73.54 - $97.8 $132 Million - $175 Million
1,791,755 Added 19169.31%
1,801,102 $170 Million
Q1 2019

May 15, 2019

BUY
$48.7 - $86.6 $455,198 - $809,450
9,347 New
9,347 $748,000

Others Institutions Holding BPMC

About Blueprint Medicines Corp


  • Ticker BPMC
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 59,719,600
  • Market Cap $6.59B
  • Description
  • Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibit...
More about BPMC
Track This Portfolio

Track Invesco Ltd. Portfolio

Follow Invesco Ltd. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Invesco Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Invesco Ltd. with notifications on news.